Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Actinogen: Edison Open House Healthcare 2022

Actinogen: Edison Open House Healthcare 2022

Actinogen Medical — 5 videos in collection

More on this equity

Actinogen Medical is an ASX-listed Australian biotech developing lead asset Xanamem, a brain-penetrant 11beta-HSD1 inhibitor designed to treat cognitive impairment and other symptoms that occurs in chronic neurological diseases.

• Tell us about the company’s approach to treating Alzheimer’s disease?
• Does it offer a cure or mainly symptom management?
• Actinogen’s drug candidate, Xanamem, targets cortisol in the brain. How is this different from systemic targeting?
• Are there any other neurological diseases, characterised by high levels of cortisol in the brain, which you might also focus on?
• What level of data have you collected with Xanamem so far?
• There has been an increased focus on the treatment field for Alzheimer’s disease. How does this affect Actinogen?
• Which milestones should investors focus on in the coming year?
• Are you planning to add further indications in the longer term?

< Previous
Next >

You may also be interested in these:

Healthcare

Actinogen Medical – executive interview

Healthcare

Actinogen Medical - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free